All About AMPYRA®
AMPYRA® Prescription and Service Requests
Share Print

Clinical Trial Design and Efficacy Data

AMPYRA® (dalfampridine) Extended Release Tablets is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

AMPYRA® (dalfampridine) Extended Release Tablets study design in two randomized, well-controlled clinical trials

  • Primary measure of efficacy was the prospective analysis of consistent response on walking speed as assessed by the T25FW
  • Responder definition:
    • Walking speed faster 3 of 4 visits during treatment than any maximum speed during 5 off-drug visits

Visit schedule and design for pivotal Trial 1

visit schedule and design for pivotal trial 1



Visit schedule and design for pivotal Trial 2

visit schedule and design for pivotal trial 2


Study schedules and design: After a screening visit for assessment of eligibility, patients returned at visit 0 and received single-blind placebo medication for 2 weeks. At visit 2, patients were randomly assigned to dalfampridine or placebo treatment, and returned for 4 visits (visits 3-6) over the course of the 9 or 14 weeks of double-blind treatment. Active treatment discontinued at visit 6 in Trial 1, and patients returned 2 and 4 weeks after treatment for follow-up visits 7 and 8. In Trial 2, visit 7 was an active treatment visit, but was not included in the efficacy assessment. This on-drug visit was used to determine dalfampridine plasma concentrations and to assess the duration of drug effect through the 12-hour dosing interval. Active treatment ended here and patients returned 2 weeks later for follow-up visit 8.

A Closer Look
  • No differences in effectiveness were detected based on degree of impairment, age, gender, or body mass index.5

Next: Patient Range

Indication

AMPYRA® (dalfampridine) Extended Release Tablets is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

IMPORTANT SAFETY INFORMATION

The use of AMPYRA is contraindicated in the following conditions: History of seizure, or moderate or severe renal impairment.

AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.

Patients should discontinue use of any product containing 4-aminopyridine prior to initiating treatment with AMPYRA in order to reduce the potential for dose-related adverse reactions, including seizures.

Seizures: AMPYRA can cause seizures. The risk of seizures increases with increasing AMPYRA doses. AMPYRA is contraindicated in patients with a prior history of seizure. Discontinue AMPYRA use if seizure occurs.

Renally impaired patients: AMPYRA is contraindicated in patients with moderate or severe renal impairment (CrCl ≤ 50 mL/min); the risk of seizures in patients with mild renal impairment (CrCl 51-80 mL/min) is unknown, but AMPYRA plasma levels in these patients may approach those seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures; estimated CrCl should be known before initiating treatment with AMPYRA.

Urinary tract infections were reported more frequently as adverse reactions in patients receiving AMPYRA 10 mg twice daily compared to placebo.

The most common adverse events (incidence ≥ 2% and at a rate greater than the placebo rate) for AMPYRA in MS patients were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain.

The risk of adverse events, including seizures, increases with increasing AMPYRA doses. No additional benefit was demonstrated at doses greater than 10 mg twice daily.

There are no adequate and well-controlled studies of AMPYRA in pregnant women. AMPYRA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Safety and effectiveness of AMPYRA in patients younger than 18 years of age have not been established.

Clinical studies of AMPYRA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

For more information, please see the complete Prescribing Information, including the Medication Guide.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
You may also contact Acorda Therapeutics, Inc. at 1-800-367-5109.

AMPYRA® is a registered trademark of Acorda Therapeutics®, Inc.
AMPYRA® is marketed by Acorda Therapeutics®, Inc and manufactured under license from Alkermes Pharma Ireland Ltd.
© 2011 Acorda Therapeutics®, Inc. All rights reserved.

  is a registered trademark of Acorda Therapeutics®, Inc.

AMP193